2025 · 3rd Quarter (July 1 - Sep 30)

PFIZER INC.

Filed by PFIZER INC..

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Amendment
Posted: Jan 23, 2026
Income: Not reported
Expenses: $2,810,000.00
Registrant: PFIZER INC.
Client: PFIZER INC.
Filing UUID: dc74e8c4-ea29-4887-84c7-6fc8cc3e22db
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing

Literal federal measure citations: HR 4317, HR 2214, S 832, S 864, S 882, H.R. 5256

MMM · Medicare/Medicaid

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics

Literal federal measure citations: S 1702

TRD · Trade (domestic/foreign)

International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.